{"id":15205,"date":"2021-07-05T15:33:45","date_gmt":"2021-07-05T13:33:45","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=15205"},"modified":"2024-12-11T13:57:51","modified_gmt":"2024-12-11T12:57:51","slug":"zanubrutinib-dans-le-traitement-des-lymphomes-a-cellules-du-manteau-en-rechute","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/zanubrutinib-dans-le-traitement-des-lymphomes-a-cellules-du-manteau-en-rechute\/","title":{"rendered":"Zanubrutinib dans le traitement des lymphomes \u00e0 cellules du manteau en rechute"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1302px;margin-left: calc(-5% \/ 2 );margin-right: calc(-5% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.375%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.375%;--awb-width-medium:100%;--awb-spacing-right-medium:2.375%;--awb-spacing-left-medium:2.375%;--awb-width-small:100%;--awb-spacing-right-small:2.375%;--awb-spacing-left-small:2.375%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p>R\u00e9f. : HematoStat.net ; 2 (3) : R23<\/p>\n<p><a href=\"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/12\/2577\/476187\/Zanubrutinib-for-the-treatment-of-relapsed-or\">Tam CS, Opat S, Simpson D, Cull G, Munoz J, Phillips TJ, Kim WS, Rule S, Atwal SK, Wei R, Novotny W, Huang J, Wang M, Trotman J. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021 Jun 22;5(12):2577-2585. doi: 10.1182\/bloodadvances.2020004074. PMID: 34152395.<\/a><\/p>\n<h3>R\u00e9sum\u00e9<\/h3>\n<p>Dans un essai multicentrique de phase \u00bd, un sous-groupe de 32 patients atteints de lymphome \u00e0 cellules du manteau (MCL) en rechute ou r\u00e9fractaires (R\/R) ont re\u00e7u du zanubrutinib, un inhibiteur de BTK, \u00e0 la dose de 160 mg x 2\/j (n = 14) ou 320 mg x 1\/j (n = 18). L\u2019\u00e2ge m\u00e9dian \u00e9tait de 70,5 ans, le suivi m\u00e9dian \u00e9tait de 18,8 mois. Il s\u2019agissait d\u2019une population de haut risque : 87,5 % de stade IV, MIPI \u00e9lev\u00e9 pour 1\/3 des patients, 25 % de maladies r\u00e9fractaires. Le nombre m\u00e9dian de lignes ant\u00e9rieures \u00e9tait de 1 (rang 1-4), et seulement 15,6 % des patients avaient re\u00e7u une autogreffe. L\u2019ORR \u00e9tait de 84,4 %, avec 25 % de CR (pas de diff\u00e9rence de r\u00e9ponses entre les deux sch\u00e9mas posologiques). La PFS m\u00e9diane \u00e9tait de 21,1 mois. 18 patients ont arr\u00eat\u00e9 le traitement : 10 pour maladie progressive, 8 pour toxicit\u00e9. Le traitement \u00e9tait bien tol\u00e9r\u00e9, avec notamment seulement 3 h\u00e9morragies majeures et 2 fibrillations atriales. Les effets ind\u00e9sirables les plus fr\u00e9quents \u00e9taient les diarrh\u00e9es, la constipation, les contusions et les infections respiratoires hautes.<\/p>\n<h3>Dans nos pratiques<\/h3>\n<p>Avec un profil de tol\u00e9rance qui semble meilleur que celui de l\u2019ibrutinib, le zanubrutinib, qui est un inhibiteur plus s\u00e9lectif de BTK, semble \u00eatre une arme th\u00e9rapeutique tr\u00e8s prometteuse dans les MCL R\/R.<\/p>\n<h3>Le regard du statisticien<\/h3>\n<p>Cette publication d\u2019essai de phase I\/II propose un rendu tr\u00e8s complet des r\u00e9sultats (description, histogramme d\u2019\u00e9volution par patient de la maladie, courbes de Kaplan-Meier). Le plus est le <em>forest-plot <\/em>du taux de r\u00e9ponse globale (ORR) calcul\u00e9 pour chaque sous-groupe (homme <em>vs <\/em>femme, par classes d\u2019\u00e2ge, stade de la maladie, score MIPI, etc.).<\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":15206,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[36],"tags":[142,143],"ppma_author":[442],"class_list":["post-15205","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-revue-de-presse","tag-mcl","tag-zanubrutinib","author-marion"],"aioseo_notices":[],"authors":[{"term_id":442,"user_id":2,"is_guest":0,"slug":"marion","display_name":"HematoStat.net (M)","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png"},"first_name":"HematoStat.net (M)","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=15205"}],"version-history":[{"count":1,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15205\/revisions"}],"predecessor-version":[{"id":18190,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15205\/revisions\/18190"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=15205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=15205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=15205"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=15205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}